Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Sara Freeman

  • 1
    News

    Heart failure hospitalization risk lower with SGLT2 inhibitors than GLP-1 RAs

    September 27, 2021

    SGLT2 inhibitor versus GLP-1 RA use was associated with a significantly lower rate of hospitalization for heart failure in people with diabetes.

  • 1
    News

    Mavrilimumab may aid severe COVID-19 recovery

    June 10, 2021

    The granulocyte/macrophage-colony stimulating factor (GM-CSF) blocker reduced the need for mechanical ventilation and death by day 29 versus placebo.

  • 1
    News

    Rheumatologic disease activity an important influencer of COVID-19 death risk

    February 5, 2021

    COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from COVID-19.

  • 1
    News

    EULAR’s COVID-19 recommendations offer no surprises

    June 11, 2020

    The provisional recommendations cover four themes: general measures and preventing SARS-CoV-2 infection, managing patients without COVID-19 and those with the infection, and preventing COVID-19 lookalikes.

  • 1
    News

    Age leads COVID-19 hospitalization risk factors in RMDs

    June 10, 2020

    Glucocorticoid use, cardiovascular comorbidity, and male gender were also found to increase the risk of hospitalization from COVID-19 in inflammatory rheumatic diseases.

  • 1
    News

    ACR gives guidance on rheumatic disease management during pandemic

    May 12, 2020

    When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be stopped or held.

  • News

    Lopinavir-ritonavir trial results ‘disappointing’ for severe COVID-19

    March 19, 2020

    But patients in the lopinavir/ritonavir group had a shorter stay in the intensive care unit than did those in the standard-care group.

  • 1
    News

    Culture change needed to improve gender inequalities in medicine

    February 17, 2019

    LONDON – A group of prominent female physicians and thought-leaders discuss cultural changes needed to address gender inequality in science and medicine.

  • 1
    News

    Fund projects, not people to address gender bias in research funding

    February 13, 2019

    LONDON – Female investigators are less likely to secure research funding than men simply because they are women, according to research published in The Lancet.

  • 1
    News

    Nasal glucagon ‘viable alternative’ to intramuscular administration

    November 20, 2018

    BERLIN – Severe hypoglycemia was reversed successfully in all patients with type 1 diabetes mellitus given nasal glucagon.

  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences